MannKind (MNKD) Q2 Revenue Rises 6%
(NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales. However, this figure was nearly $2.3 million below the $78.8 million analyst consensus. Non-GAAP earnings per share remained flat year over year at $0.05, aligned exactly with expectations. Progress in key pipeline programs and substantial increases in operating expenses raised execution questions as the company pursues growth.
Source: Analyst estimates for the quarter provided by FactSet.
(NASDAQ:MNKD) develops and manufactures inhalable therapies, mainly targeting diabetes and rare lung diseases. Its flagship product is Afrezza, an inhaled insulin powder designed to offer rapid-acting blood sugar control for people with diabetes. MannKind's business also includes V-Go, a wearable insulin delivery device, and partnership-derived revenues from production and royalties on Tyvaso DPI, an inhaled treatment for pulmonary hypertension developed by United Therapeutics.
Source Fool.com
MannKind Corp. Aktie
Mehrere Buy-Einschätzungen geben MannKind Corp. den Vorteil, ohne Sell-Einschätzungen.
Die Community erwartet für MannKind Corp. ein Kursziel von 9 €, was den aktuellen Kurs von 4.39 € mehr als verdoppeln würde.
